Literature DB >> 33261133

High-Plex and High-Throughput Digital Spatial Profiling of Non-Small-Cell Lung Cancer (NSCLC).

James Monkman1,2,3, Touraj Taheri4,5, Majid Ebrahimi Warkiani6, Connor O'Leary1,2,3,7, Rahul Ladwa5,7, Derek Richard1,2,3, Ken O'Byrne1,2,3,7, Arutha Kulasinghe1,2,3,8.   

Abstract

Profiling the tumour microenvironment (TME) has been informative in understanding the underlying tumour-immune interactions. Multiplex immunohistochemistry (mIHC) coupled with molecular barcoding technologies have revealed greater insights into the TME. In this study, we utilised the Nanostring GeoMX Digital Spatial Profiler (DSP) platform to profile a non-small-cell lung cancer (NSCLC) tissue microarray for protein markers across immune cell profiling, immuno-oncology (IO) drug targets, immune activation status, immune cell typing, and pan-tumour protein modules. Regions of interest (ROIs) were selected that described tumour, TME, and normal adjacent tissue (NAT) compartments. Our data revealed that paired analysis (n = 18) of matched patient compartments indicate that the TME was significantly enriched in CD27, CD3, CD4, CD44, CD45, CD45RO, CD68, CD163, and VISTA relative to the tumour. Unmatched analysis indicated that the NAT (n = 19) was significantly enriched in CD34, fibronectin, IDO1, LAG3, ARG1, and PTEN when compared to the TME (n = 32). Univariate Cox proportional hazards indicated that the presence of cells expressing CD3 (hazard ratio (HR): 0.5, p = 0.018), CD34 (HR: 0.53, p = 0.004), and ICOS (HR: 0.6, p = 0.047) in tumour compartments were significantly associated with improved overall survival (OS). We implemented both high-plex and high-throughput methodologies to the discovery of protein biomarkers and molecular phenotypes within biopsy samples, and demonstrate the power of such tools for a new generation of pathology research.

Entities:  

Keywords:  NSCLC; differential protein expression; nanostring GeoMx digital spatial profiling; spatial; tissue microarray; tumour microenvironment

Year:  2020        PMID: 33261133     DOI: 10.3390/cancers12123551

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  11 in total

Review 1.  Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx® Digital Spatial Profiler.

Authors:  Sharia Hernandez; Rossana Lazcano; Alejandra Serrano; Steven Powell; Larissa Kostousov; Jay Mehta; Khaja Khan; Wei Lu; Luisa M Solis
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

Review 2.  Immune Checkpoint Inhibitors in Cancer Therapy.

Authors:  Yavar Shiravand; Faezeh Khodadadi; Seyyed Mohammad Amin Kashani; Seyed Reza Hosseini-Fard; Shadi Hosseini; Habib Sadeghirad; Rahul Ladwa; Ken O'Byrne; Arutha Kulasinghe
Journal:  Curr Oncol       Date:  2022-04-24       Impact factor: 3.109

3.  ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.

Authors:  Wei Nie; Zhi-Jie Wang; Kai Zhang; Bing Li; Yi-Ran Cai; Feng-Cai Wen; Ding Zhang; Yue-Zong Bai; Xue-Yan Zhang; Shu-Yuan Wang; Lei Cheng; Hua Zhong; Li Liu; Jie Wang; Bao-Hui Han
Journal:  BMC Med       Date:  2022-05-05       Impact factor: 11.150

4.  Profiling of lung SARS-CoV-2 and influenza virus infection dissects virus-specific host responses and gene signatures.

Authors:  Arutha Kulasinghe; Chin Wee Tan; Anna Flavia Ribeiro Dos Santos Miggiolaro; James Monkman; Habib SadeghiRad; Dharmesh D Bhuva; Jarbas da Silva Motta Junior; Caroline Busatta Vaz de Paula; Seigo Nagashima; Cristina Pellegrino Baena; Paulo Souza-Fonseca-Guimaraes; Lucia de Noronha; Timothy McCulloch; Gustavo Rodrigues Rossi; Caroline Cooper; Benjamin Tang; Kirsty R Short; Melissa J Davis; Fernando Souza-Fonseca-Guimaraes; Gabrielle T Belz; Ken O'Byrne
Journal:  Eur Respir J       Date:  2022-06-02       Impact factor: 33.795

5.  The Importance of the Tumor Microenvironment to Understand Tumor Origin, Evolution, and Treatment Response.

Authors:  Jose M Ayuso; Ignacio Ochoa Garrido
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.639

6.  Macrophages-based immune-related risk score model for relapse prediction in stage I-III non-small cell lung cancer assessed by multiplex immunofluorescence.

Authors:  Xiang-Rong Wu; Hao-Xin Peng; Miao He; Ran Zhong; Jun Liu; Yao-Kai Wen; Cai-Chen Li; Jian-Fu Li; Shan Xiong; Tao Yu; Hong-Bo Zheng; Yan-Hui Chen; Jian-Xing He; Wen-Hua Liang; Xiu-Yu Cai
Journal:  Transl Lung Cancer Res       Date:  2022-04

Review 7.  Multiplex Tissue Imaging: Spatial Revelations in the Tumor Microenvironment.

Authors:  Stephanie van Dam; Matthijs J D Baars; Yvonne Vercoulen
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

8.  Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.

Authors:  Qian Chen; Xiaoling Shang; Ni Liu; Xinchun Ma; Wenfei Han; Xiuwen Wang; Yanguo Liu
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

9.  Characteristics of hypoxic tumor microenvironment in non-small cell lung cancer, involving molecular patterns and prognostic signature.

Authors:  Zhanghao Huang; Shuo Wang; Hai-Jian Zhang; You Lang Zhou; Xin Tang; Jia-Hai Shi
Journal:  Transl Lung Cancer Res       Date:  2021-05

10.  Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler.

Authors:  Helga Bergholtz; Jodi M Carter; Alessandra Cesano; Maggie Chon U Cheang; Sarah E Church; Prajan Divakar; Christopher A Fuhrman; Shom Goel; Jingjing Gong; Jennifer L Guerriero; Margaret L Hoang; E Shelley Hwang; Hellen Kuasne; Jinho Lee; Yan Liang; Elizabeth A Mittendorf; Jessica Perez; Aleix Prat; Lajos Pusztai; Jason W Reeves; Yasser Riazalhosseini; Jennifer K Richer; Özgür Sahin; Hiromi Sato; Ilana Schlam; Therese Sørlie; Daniel G Stover; Sandra M Swain; Alexander Swarbrick; E Aubrey Thompson; Sara M Tolaney; Sarah E Warren
Journal:  Cancers (Basel)       Date:  2021-09-04       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.